ResMed Inc. closed 18.65% short of its 52-week high of $263.05, which the company reached on January 30th.

ResMed Inc. closed 19.96% below its 52-week high of $263.05, which the company achieved on January 30th.

Resmed (RMD) announced the publication of a meta-analysis in The Lancet Respiratory Medicine, demonstrating that CPAP therapy significantly reduces the risk of death for people with obstructive ...

Morgan Stanley initiated coverage of ResMed (RMD) with an Overweight rating and A$313 price target The company has a market-leading position in the obstructive sleep apnea market and valuations ...

MLB, Topps and Nike have partnered to recognize baseball's elite performers from last season with custom gold-embellished MLB logos on their jerseys that will then be used to create trading cards.